Lin BioScience Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to eva… Read more
Market Cap & Net Worth: Lin BioScience Inc. (6696)
Lin BioScience Inc. (TWO:6696) has a market capitalization of $982.09 Million (NT$32.49 Billion) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #8480 globally and #220 in its home market, demonstrating a -3.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lin BioScience Inc.'s stock price NT$392.00 by its total outstanding shares 82892000 (82.89 Million).
Lin BioScience Inc. Market Cap History: 2018 to 2026
Lin BioScience Inc.'s market capitalization history from 2018 to 2026. Data shows growth from $93.20 Million to $982.09 Million (32.28% CAGR).
Lin BioScience Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lin BioScience Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6696 by Market Capitalization
Companies near Lin BioScience Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Lin BioScience Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Lin BioScience Inc. Historical Marketcap From 2018 to 2026
Between 2018 and today, Lin BioScience Inc.'s market cap moved from $93.20 Million to $ 982.09 Million, with a yearly change of 32.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$982.09 Million | -1.38% |
| 2025 | NT$995.87 Million | +189.09% |
| 2024 | NT$344.48 Million | +20.61% |
| 2023 | NT$285.61 Million | -34.29% |
| 2022 | NT$434.68 Million | -6.97% |
| 2021 | NT$467.25 Million | +82.84% |
| 2020 | NT$255.54 Million | +234.32% |
| 2019 | NT$76.44 Million | -17.98% |
| 2018 | NT$93.20 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Lin BioScience Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $982.09 Million USD |
| MoneyControl | $982.09 Million USD |
| MarketWatch | $982.09 Million USD |
| marketcap.company | $982.09 Million USD |
| Reuters | $982.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.